2021 Press Releases

Edgewise

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)
December 21, 2021

Deciphera logo

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
December 21, 2021

Arvinas logo

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
December 10, 2021

Kitcheck logo

Kit Check and Fagron Partner to Launch RFID-tagged 503B Products in February 2022
December 8, 2021

Cleerly

CLEERLY NAMED TO THE 2021 CB INSIGHTS DIGITAL HEALTH 150
December 8, 2021

Kyruus logo

Ochsner Health Makes Finding the Right Provider Easier with Solutions from Kyruus
December 7, 2021

Neurana Pharmaceuticals

Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study
November 29, 2021

Deciphera logo

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
November 22, 2021

PDS Biotechnology

PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute
November 8, 2021

Aptinyx logo

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
October 27, 2021

TigerConnect

TigerConnect’s Alarm Management and Event Notification Solution Mitigates “Alarm Fatigue” in Demanding Clinical Environments
October 26, 2021

Cleerly

CLEERLY APPOINTS JIM HARTMAN AS CHIEF REVENUE OFFICER
October 18, 2021

Deciphera logo

Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
October 12, 2021

Cogent Bioscience

Cogent Biosciences Presents New Preclinical Data Demonstrating Bezuclastinib as a Differentiated KIT Inhibitor with Minimal Brain Penetratio
October 7, 2021

Deciphera logo

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 7, 2021

Kyruus logo

Privia Health Uses Kyruus’ Digital Patient Access Platform to Help Empower Consumers and Drive Practice Growth
October 5, 2021

Kitcheck logo

Kit Check Enters into a Reseller Agreement with Govplace to allow Government Hospitals to increase Pharmacy Visibility with RFID Enabled Kit and Tray Processing to Increase Medication Intelligence
September 22, 2021

Deciphera logo

Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
September 17, 2021

Cice Molecules

DICE Therapeutics Announces Pricing of Upsized Initial Public Offering
September 14, 2021

PDS Biotechnology

PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
September 9, 2021

Kitcheck logo

Kit Check Hires New Chief Technology Officer
August 30, 2021

TigerConnect

TigerConnect Announces Expanded Product Suite to Revolutionize Clinical Collaboration and Cut Care Costs
August 5, 2021

Rallybio Corporation Announces Pricing of Initial Public Offering
July 28, 2021

Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
July 2, 2021

Arvinas logo

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
July 22, 2021

Addex

ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE
June 29, 2021

Cleerly

Cleerly Launches with $43 Million Series B to Provide a New Standard of Care for the Leading Cause of Death – Heart Disease
June 21, 2021

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
June 21, 2021

 Braeburn

Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
June 15, 2021

Aptinyx logo

Aptinyx Provides Update on NYX-783 Development Program for the Treatment of Post-Traumatic Stress Disorder
June 15, 2021

Neurana Pharmaceuticals

Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
June 7, 2021

Addex

ADDEX STARTS PHASE 2 CLINICAL STUDY OF ADX71149 FOR EPILEPSY
June 4, 2021

Deciphera logo

Deciphera Pharmaceuticals Presents Data from QINLOCK® and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 4, 2021

Qlaris Bio logo

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma
April 15, 2021

Aptinyx logo

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
April 6, 2021

Brightinsight logo

BrightInsight Announces $101M in Series C Funding led by General Catalyst
March 30, 2021

Edgewise

Edgewise Therapeutics Announces Pricing of Initial Public Offering
March 25, 2021

Brightinsight logo

BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
March 16, 2021

ReViral

ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China
March 2, 2021

Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021

Iterum Therapeutics

Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
February 9, 2021

PassageBio

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
February 8, 2021

Kitcheck logo

Kit Check®’s Bluesight® for Controlled Substances is Announced as Best in KLAS for Drug Diversion Monitoring in 2021 Best in KLAS Report
February 3, 2021

Iterum Therapeutics

Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
February 3, 2021

Iterum Therapeutics

Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch
February 1, 2021

Truveris logo

TRUVERIS EXPANDS LEADERSHIP TEAM WITH KEY APPOINTMENTS
January 20, 2021

 Addex Therapeutics

ADDEX ANNOUNCES PRICING OF $10.0 MILLION GLOBAL OFFERING
January 7, 2021

Harpoon Therapeutics logo

HARPOON THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
January 6, 2021

Harpoon Therapeutics logo

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS
January 4, 2021

PassageBio

HARPOON THERAPEUTICS DOSES FIRST PATIENT WITH HPN328, AN ANTI-DLL3 T CELL ENGAGER FOR TREATMENT OF SMALL CELL LUNG CANCER AND OTHER DLL3-ASSOCIATED TUMORS
January 4, 2021